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Abstract
Soluble receptor decoy inhibitors, including receptor-immunogloubulin (Ig) fusion proteins, have shown promise as
candidate anthrax toxin therapeutics. These agents act by binding to the receptor-interaction site on the protective antigen
(PA) toxin subunit, thereby blocking toxin binding to cell surface receptors. Here we have made the surprising observation
that co-administration of receptor decoy-Ig fusion proteins significantly delayed, but did not protect, rats challenged with
anthrax lethal toxin. The delayed toxicity was associated with the in vivo assembly of a long-lived complex comprised of
anthrax lethal toxin and the receptor decoy-Ig inhibitor. Intoxication in this system presumably results from the slow
dissociation of the toxin complex from the inhibitor following their prolonged circulation. We conclude that while receptor
decoy-Ig proteins represent promising candidates for the early treatment of B. anthracis infection, they may not be suitable
for therapeutic use at later stages when fatal levels of toxin have already accumulated in the bloodstream.
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Introduction
Anthrax toxin is the major virulence factor of B. anthracis, the
causative agent of anthrax. There are two forms of anthrax toxin,
each of which contains the protective antigen (PA) toxin subunit.
Edema toxin (EdTx) pairs PA with edema factor (EF), a calcium
and calmodulin-dependent adenylate cyclase; and lethal toxin
(LeTx) is comprised of PA and lethal factor (LF), a zinc-dependent
metalloprotease that cleaves and inactivates MAP kinase kinase
signaling pathways [1,2,3].
The first step of intoxication involves binding of an 83 kD form
of PA (PA83) to cell surface receptors. Two different cellular
receptors for PA83 have been identified, designated as ANTXR1
and ANTXR2 [4,5]. PA83 binds to an extracellular domain of
each receptor that is related in structure to the integrin-like von
Willebrand Factor type A (VWA) domain [4,5]. Following
receptor-binding, PA83 is cleaved to a 63 kD form by a cell
surface furin-like protease, and the resultant PA63 fragment
spontaneously assembles into either heptameric or octameric
prepore complexes [6,7,8,9]. Alternatively, these oligomeric PA
complexes may assemble prior to receptor binding following PA83
to PA63 cleavage by a serum protease within the bloodstream of
infected animals [10,11]. The toxin complexes are taken up into
cells by receptor-mediated endocytosis [12,13,14,15]. Entry into
an acidic endosomal compartment stimulates PA63 prepore-to-
pore conversion and LF and EF translocation into the cytosol
leading to toxicity [16].
There is a great deal of interest in developing anthrax antitoxins
(reviewed in [17]). The rationale for developing these inhibitors is
that they may complement existing vaccine and antibiotic-based
therapies, and may be especially useful to treat disease caused by
either vaccine-, or antibiotic-resistant bacterial strains. Several
different anthrax anti-toxins are being developed including
monoclonal antibodies, small molecule inhibitors, receptor decoys,
substrate analogs, and dominant-negative toxin subunits.
We first demonstrated the utility of a soluble receptor decoy as a
candidate anthrax therapeutic [18]. That inhibitor, based upon
the soluble VWA domain of ANTXR2, had several desirable
features including a high binding affinity for PA (Kd=170 pM)
[19]. The receptor decoy inhibitor also efficiently neutralized both
wild-type PA, as well as altered forms of PA that were engineered
to be resistant to therapeutic monoclonal antibodies [20,21].
Several other groups have generated receptor decoy inhibitors
by fusing the ANTXR2 VWA domain to the Fc portions of either
human IgG1 or IgG2 [21,22]. These reagents have the additional
benefit of having an increased circulation half-life in vivo, thereby
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34611increasing their antitoxin potencies. The receptor decoy-IgG2
protein protected rats against short-term intoxication by anthrax
lethal toxin, and also protected mice against killing following
intratracheal administration of attenuated B. anthracis Sterne spores
[22]. The receptor decoy-IgG1 protein protected rabbits against
killing following an inhalational challenge with fully virulent B.
anthracis Ames spores [21].
In this study we also generated and tested several different
receptor decoy-Ig fusion proteins in vitro and in vivo. In contrast to
previous reports, we found that these inhibitors delayed killing, but
did not protect, rats that were challenged with a lethal dose of
anthrax lethal toxin. The mechanism of delayed toxicity was
studied by following the fate of the toxin subunits following co-
administration with anthrax lethal toxin.
Results
Our previous studies showed that a soluble, bacterially-
produced form of the ANTXR2 VWA domain (termed receptor
decoy inhibitor, or RDI) protected against LeTx challenge in rats,
but only when it was administered concurrently or within
5 minutes of dosing with toxin [18]. That RDI protein was
comprised of ANTXR2 amino acid residues 1–232 fused to a
MycHis epitope tag [18].
In an effort to improve the potency of the receptor decoy we set
out to generate a long-lived fusion protein comprised of the
ANTXR2 VWA domain fused to the Fc portion of an IgG1
antibody, since that is a commonly used strategy to increase serum
half-life of proteins. The Fc portion used contained two amino acid
mutations (T250Q and M482L) that further extend the serum
half-lives of IgG1 fusion proteins by approximately 2-fold [23].
The recombinant receptor decoy-Fc gene, designated as RDI-
eIgG1 encoded amino acid residues 1 to 226 of ANTXR2 fused to
the Fc portion of the altered IgG1 fragment in plasmid pFUSE-
hIgG1e1-Fc1 (Invivogen) (Figure 1A). This DNA construct was
transiently transfected into human 293 cells, and the approxi-
mately 50 kD RDI-eIgG1 fusion protein was purified from the
extracellular supernatants by protein A-chromatography
(Figure 1B).
The plasma half-life of the RDI-eIgG1 protein was compared in
rats with that of the bacterially produced RDI [19]. Rats were
injected intravenously with these proteins. Animals were bled at
varying times post-dosing as shown in Figure 1C. Plasma
concentrations were measured using a quantitative ELISA capture
assay for the ANTXR2 VWA domain. For the RDI protein, the
protein demonstrated first-order elimination and the t1/2 was
shown to be 10.4 min (Figure 1C); calculated volume of
distribution 48.6 ml; clearance 3259 ml/min, and area under
the concentration-time curve (AUC) 282.5 mg-min/ml. In con-
trast, the RDI-eIgG1 protein showed a much longer t1/2 of
2115 min (,35 hrs); volume of distribution 39.3 ml; clearance
12.9 ml/min, and AUC of 3.9610
6 mg-min/ml. The results of t1/2
and clearance measurements confirm that the RDI-eIgG1 protein
circulated in plasma for much longer than the RDI protein, and
the similarities in volume of distribution suggest that RDI-eIgG1
likely did not distribute to other tissues or sites in comparison to
RDI.
The RDI-eIgG1 protein was compared to RDI in an in vitro
intoxication assay to establish its inhibitory activity as a receptor
decoy. In this approach, inhibitors were mixed at varying molar
ratios of (VWA/I:PA) with a fixed amount of LF and added to
RAW264.7 cells. Intoxication was measured using an assay that
monitors cellular ATP levels as a measure of cell viability. Both
inhibitors showed similar inhibition profiles (Figure 1D). Consis-
tent with previous published reports [21,22], the RDI-eIgG1
protein showed some efficacy in protecting A/J mice from death
following intraperitoneal injection with a lethal dose of B. anthracis
Sterne spores. (Figure 2).
The RDI-eIgG1 fusion protein was also tested for its efficacy in
protecting rats against challenge with a lethal dose of LeTx. Rats
were injected i.v. with LeTx (40 mg of PA and 12 mg of LF) in
combination with PBS, RDI, or RDI-eIgG1. Animals that had
received LeTx alone died between 60 and 90 minutes after toxin
challenge, while, as expected, all animals that received a 2:1 molar
ratio (RDI:PA) and LF all survived (Fig. 3). Surprisingly, when the
RDI-eIgG1 protein was co-injected with LeTx (at a similar 2:1
ratio of ANTXR2 VWA-I domain: PA), the animals initially
survived, but began to die approximately 20 hours after dosing
(Fig. 3). By 3 days post-challenge, 50% of the animals in the group
had died. This result was reproducible in six independent
experiments (Table 1). Administration of a 2.5-fold higher dose
of RDI-eIgG1 either alone, or in combination with PA, did not
result in any morbidity, toxicity or pathology (Fig. 4), indicating
that the complete LeTx (PA+LF) was required to produce the
observed delayed toxicity. RDI-eIgG1 was also not found to be
immunogenic in rats (data not shown). Together these results
demonstrated that RDI-eIgG1, like RDI, provided initial
protection when it was co-administered with a lethal dose of
LeTx to animals. However, in contrast to the effective long-term
protection seen with the short-lived RDI protein following co-
administration with a fatal dose of toxin, the longer-lived RDI-
eIgG1 protein was much less effective at providing long-term
protection under this condition. These data indicated that the
delayed time to death seen with the RDI-eIgG1 protein might be
associated with its prolonged circulation half-life relative to RDI.
Since PA-ANTXR2 complexes are extremely stable, with a
lifetime interaction of approximately 30 hours in vitro [19], we
reasoned that the delayed toxicity might be due to the slow release
of oligomeric PA63/LF complexes that had assembled on the long-
lived RDI-eIgG1 protein in vivo. To address this possibility, we
asked whether LF and PA could be co-purified with RDI-eIgG1 at
a late time point following co-administration. Rats were injected
through jugular vein cannulas with 40 mgP A 83,1 2mg LF, and
122 mg of RDI-eIgG1 (representing a 5:1 molar ratio of ANTXR2
VWA/I domain:PA). Blood was collected 15 hours after injection,
serum was prepared, and immediately subjected to Protein G-
sepharose precipitation (Roche Diagnostics, Mannheim, Ger-
many) to purify RDI-eIgG1 and any associated proteins from the
rat serum. Immunoprecipitated samples were subjected to SDS-
PAGE and to immunoblotting using either a goat-anti-PA
antibody (to detect PA83 or PA63) or a goat anti-LF antibody.
Both LF and the 63 kD form of PA were co-purified with RDI-
eIgG1 (Figure 5). These studies indicated that a PA63/LF complex
was associated with the RDI-eIgG1 protein in the rat circulation at
15 hours post-injection. PA63 is known to be generated in vivo from
PA83 by serum protease cleavage [10,11]. We conclude that the
PA63 present in these complexes is in an oligomeric form, because
LF is known to bind to oligomeric, but not monomeric, PA [24].
These findings are consistent with a model in which oligomeric
LeTx complexes assemble on circulating RDI-eIgG1, and that the
slow release of these assembled toxin complexes may be
responsible for the delayed toxicity seen following co-administra-
tion of LeTx and RDI-eIgG1.
To determine whether this delayed toxicity was specific to the
extremely long-lived RDI-eIgG1 protein, we generated other
receptor decoy-Ig proteins containing the Fc portions of either
wild-type IgG2 or IgG1. Vuyisich et al. previously showed that a
receptor decoy-IgG2 fusion protein protected rats for a short
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reported whether longer time points after intoxication were
studied [22]. That receptor decoy-IgG2 protein also protected
mice against killing following intratracheal administration of
attenuated B. anthracis Sterne spores [22]. A separate study by
Wycoff et al. showed that a receptor decoy-IgG1 protein can
protect rabbits against killing following an inhalational challenge
with fully virulent B. anthracis Ames spores [21].
Our RDI-IgG1 and RDI-IgG2 constructs (Fig. 6A) were
engineered as described under Materials and Methods and
expressed in the extracellular supernatants of transiently trans-
fected 293 T cells. Both fusion proteins showed similar expression,
molecular weights, and protein yields as the RDI-eIgG1 protein
(Fig. 6B). The proteins also showed similar inhibitory concentra-
tions compared to RDI-eIgG1 when tested in an in vitro
intoxication assay on RAW264.7 cells (Fig. 6C).
The wild-type RDI-IgG1 RDI-IgG2 proteins were also tested in
vivo, and again delayed toxicity was observed in each case
(Figure 7). For each group, the animals survived for about 1
day, and by 4 days approximately half the animals in each group
Figure 1. Construction, expression and half-life of RDI and RDI-eIgG1. A. Schematic of RDI and RDI-eIgG1 constructs. VWA/I: vonWillebrand
Factor A/Integrin-like I domain. Mutations T250Q and M428L in the Fc portion confer extended circulation time. B. SimplyBlue (Invitrogen) stained gel
of RDI-eIgG1 separated on a SDS-containing10% polyacrylamide gel. Molecular weight markers are indicated. C. Detection of RDI (top panel) or RDI-
eIgG1 (bottom panel) after intravenous injection in 2 rats by ELISA analysis. Curve-fitting and half-life (t1/2) was calculated using Prism (Graph Pad,
Inc.) D. Inhibition of LeTx activity in RAW264.7 cells by RDI or RDI-eIgG1.
doi:10.1371/journal.pone.0034611.g001
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all animals (Fig. 7). These results demonstrate that the delayed
toxicity that was initially seen with the RDI-eIgG1 protein is not
due to the intrinsic extended circulation half-life of that protein
relative to the other RDI-Ig-fusion proteins, but instead is a
general feature of all the receptor decoy-IgG fusion proteins that
were tested.
Discussion
In this report we have tested the abilities of several different
receptor decoy inhibitor-IgG fusion proteins to protect rats against
challenge with a lethal dose of anthrax lethal toxin. The fusion
proteins tested contained the Fc portions of IgG1, IgG2, or an
altered form of IgG1 with increased circulation half-life. In each
case, the inhibitor treatment significantly delayed, but did not
prevent toxicity. Delayed toxicity was completely dependent upon
the addition of LF since no toxicity was observed with the receptor
decoy-Ig protein and PA alone. Delayed toxicity was associated
with the assembly of long-lived LF/PA63 complexes on the
receptor-Ig protein.
These data lead to a model in which the PA83 that was
introduced into the rat bloodstream was processed by serum
proteases [10,11] and the resultant PA63 fragment assembled into
oligomers on the receptor decoy-Ig protein where it bound LF.
Alternatively, LF may bind to the PA63 oligomers prior to binding
the RDI-Ig proteins. The LF/PA63 complexes were associated
with long-lived RDI-IgG proteins, circulating in the bloodstream
for an extended period of time. We speculate that, at a slow rate,
the toxin complex dissociates from the long-lived inhibitor leading
to death; the half-life of the PA-ANTXR2 VWA domain
interaction is estimated to be ,17 hours [19]. Although we found
that protection is independent of Ig subclass (Figure 7), it is also
possible that the toxin-receptor decoy-Ig proteins are taken up into
cells by Fc receptor-mediated endocytosis and delivered to an
Figure 2. Survival of mice following spore challenge. Female A/J
mice (8–10 weeks) were given approximately 2.9610
4 Sterne strain
spores delivered in 100 ml of water IP. The CMG2-IgG was delivered IP in
approximately 100 mg doses at 1 h, 28 h, and 52 h post infection. A
final 50 mg dose of CMG2-IgG was administered at 96 h post-infection.
Statistically significant P values were achieved for mean time to death
or euthanasia by T-test (P=0.03), and log-rank Mantel-Cox survival
curve (P=0.009).
doi:10.1371/journal.pone.0034611.g002
Figure 3. RDI-eIgG1 protects rats from LeTx challenge in the
short term but shows delayed toxicity. Male 200 gram HSD rats (5/
group) were co-injected i.v. with LeTx (40 mgP A +12 mg LF) and RDI
(19 mg) or RDI-eIgG1 (49 mg). Rats were monitored and time of death
recorded.
doi:10.1371/journal.pone.0034611.g003
Table 1. Summary of studies measuring RDI-eIgG1 protection from LeTx challenge in rats.
Study # Inhibitor Survivors/Total
Average Time to
Death (hr.)
Comparison of survival curve
(log-rank Mantel-Cox)
Comparison of TTD
unpaired t-test
1 RDI-eIgG1 2/5 56 P=0.0003 P=0.0033
None 0/5 1
2 RDI-eIgG1 0/3 112 P=0.0246 P=0.0023
None 0/3 1.5
3 RDI-eIgG1 0/5 52.8 P=0.0027 P=0.0364
None 0/4 1.2
4 RDI-eIgG1 1/5 90 P=0.0049 P=0.0001
None 0/5 1.2
5 RDI-eIgG1 0/5 77.6 P=0.0019 P=0.0015
None 0/5 1.1
Male 200 gram HSD were co-injected i.v. with LeTx (40 mgP A +12 mg LF) alone or in combination with RDI-eIgG1. Number of surviving animals in each study and the
average time to death (in hours) is reported. Statistical analyses of survival curves (log-rank Mantel-Cox) and time-to-death (Student T-test) were performed using Prism
(Graph Pad, Inc.).
doi:10.1371/journal.pone.0034611.t001
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is triggered and LF is introduced into the cellular cytoplasm. It
may be possible to discriminate between these models using
receptor-deficient mice, although in mice the kinetics of LeTx
intoxication is significantly longer than in rats (e.g. Figure 2).
Interestingly, regardless of the mode of internalization, the LF-PA
complex would have to at least partially detach from the ANTXR2-
portion to form a pore in the endosomal membrane [25].
Prior to this report there were two published studies using
receptor decoy-Ig proteins as candidate anthrax therapeutics. The
study of Viyusich et al. employed a receptor decoy-IgG2 protein
comprised of the VWA domain of ANTXR2 fused to the Fc
portion of human IgG2 [22]. In their report, the authors showed
that the ANTXR2-IgG2 protein could protect DBA/2 mice
against killing when administered 2 days after challenge with
attenuated B. anthracis Sterne spores. In a separate study, Wycoff et
al. employed a receptor decoy-IgG1 protein comprised of the
VWA domain of ANTXR2 fused to the Fc portion of IgG1 [21].
They demonstrated that this protein could protect rabbits against
death when it was administered up to 1 hour following an
intranasal challenge with fully virulent B. anthracis Ames spores.
Consistent with these findings, we have shown that treatment with
the RDI-eIgG1 protein that was engineered to have an increased
circulation half-life can protect A/J mice following intraperitoneal
challenge with B. anthracis spores (Figure 2). The study of Viyusich
and colleagues further showed that their inhibitor protected rats
against anthrax lethal toxin challenge, at least 4 days following
toxin exposure [22]. Animal survival at later time points following
a fatal dose of anthrax lethal toxin was not reported in that study.
Taken together, these previous studies and the current report
indicate that receptor decoy-Ig fusion proteins are attractive
candidate anthrax therapeutics that can prevent death if adminis-
tered shortly after bacterial infection: under these conditions, the
decoy-Ig protein can presumably neutralize the immunosuppressive
effects associated with low, sub-lethal toxin levels [26]. Receptor
decoy-based inhibitors have the added benefit that they can
neutralize wild-type, as well as altered, antibody-resistant, forms
of the toxin [20,21]. Therefore, these reagents may be particularly
useful for early treatment of infection by vaccine-, antibiotic-, or
antibody-resistant forms of B. anthracis. However, our data showing
that these inhibitors did not provide long-term protection of rats
challenged with a fatal dose of anthrax lethal toxin indicates that
they may not be effective at preventing death at later time points of
infection when fatal levels of toxin have already accumulated in the
bloodstream. Studies are ongoing in our lab to overcome this
limitation of these inhibitors by developing modified receptor
decoys with intermediate circulation half-life properties since these
altered forms of inhibitor might be expected to effectively block
death at both early and late times following infection by B. anthracis.
Materials and Methods
Ethics Statement
Research was conducted in compliance with the Animal
Welfare Act and other federal statutes and regulations relating
to animals and experiments involving animals and adheres to the
principles stated in the Guide for the Care and Use of Laboratory
Animals, National Research Council, 1996. The facility where this
research was conducted is fully accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care
International. Animal research was conducted under approved
protocol S09355 from the Institutional Animal Care and Use
Committee, University of California, San Diego.
Plasmid construction
The plasmid pRDI-eIgG1 was made by PCR-amplifying the
ANTXR2 extracellular domain from pHS003 with the primers
sCMG2For (59-CTGCAGACCGGTGAGAGGATGGTGGCG-
GAG-39) and sCMG2Rev (59-ATCTAACCATGGTGGGCTG-
CAATTCTAGGAT-39) to create a DNA fragment with an AgeI
site at the 59 end and a NcoI site at the 39 end. This fragment was
ligated into pFUSE-hIgG1e1-Fc1 (Invivogen, San Diego CA)
Figure 5. Association of PA63 and LF with RDI-eIgG1 during circulation in vivo. Rats were injected through jugular vein cannulas with a total
volume of 500 ml containing 40 mg PA, 12 mg LF, 122 mg of RDI-eIgG1 in PBS vehicle per rat. This corresponds to a 5:1 molar ratio of the VWA/I
domain:PA. Serum was prepared from blood collected 15 hours after injection and protein G sepharose was used to precipitate RDI-eIgG1 and
associated proteins from the rat serum. Samples were separated on a SDS-containing 4–12% polyacrylamide gel and analyzed by immunoblotting for
the presence of RDI-eIgG1, PA, or LF.
doi:10.1371/journal.pone.0034611.g005
Figure 4. RDI-eIgG1 alone is not toxic in rats. Male 200 gram HSD
rats (Harlan Laboratories, Indianapolis, IN) (3/group) were co-injected
i.v. with LeTx (40 mgP A +12 mg LF) alone or in combination with 49 ug
RDI-eIgG1; or were dosed i.v. with 123 mg RDI-eIgG1 alone. Rats were
monitored and time of death recorded.
doi:10.1371/journal.pone.0034611.g004
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RDI-eIgG1. The sequence of the resultant plasmid was confirmed
(Eton Bioscience Inc., San Diego CA). pRDI-IgG1 and pRDI-
IgG2 were made by digesting pRDI-eIgG1 with Age1 and Nco1 to
get the ANTXR2 insert and subcloning it between the AgeI and
NcoI sites of pFUSE-hIgG1-Fc1 or pFUSE-hIgG2-Fc1, respective-
ly (Invivogen, San Diego CA). The sequences of both resultant
plasmids were confirmed (Eton Bioscience Inc., San Diego CA).
Protein expression and purification
The RDI-Ig proteins were produced by transient transfection in
293 T cells using the transfection reagent polyethylenimine (PEI,
Polysciences Inc., Warrington PA; 25,000 MW, 1 mg/ml in H20)
in DMEM/1% FBS. 18 hours post-transfection, the extracellular
media was changed and the supernatant containing the receptor
decoy proteins was collected 48 hours later.
The proteins were purified from the crude supernatant using the
Montage Antibody Purification Kit (Millipore # LSK2ABA20,
Billerica MA). They were further concentrated using the Spin-X
UF Concentrator (Corning # 431489, Lowell MA). Protein
concentration was determined using the BCA Protein Assay Kit
(Pierce # 23227, Rockford IL). The purified and concentrated
proteins were analyzed by electrophoresis on a SDS-containing
10% polyacrylamide gel and visualized with SimplyBlue SafeStain
(Invitrogen # LC6060, Carlsbad, CA). RDI was produced and
purified from bacteria as previously described [18,19].
In vitro Intoxication Assay
Intoxication inhibition assays were performed in RAW264.7
cells as described previously [20]. RAW264.7 cells were originally
obtained from the American Type Culture Collection (ATCC).
Pharmacokinetics of RDI and RDI-Ig in rats
In vivo dosing. Male Harlan Sprague-Dawley (HSD) rats
(180–200 g, Harlan, Indianapolis, IN) were anesthetized with
isofluoranes and injected intravenously with either 900 mg of RDI
Figure 6. Construction of RDI fusion proteins with IgG1 or IgG2 Fc portions. A. Schematic of the RDI and Fc portions of the fusion proteins.
B. SimplyBlue stained gel of RDI-eIgG1, RDI-IgG1, or RDI-IgG2 separated on 10% SDS-PAGE. Molecular weight markers are indicated. C. Inhibition of
LeTx activity in RAW264.7 cells by RDI-eIgG1, RDI-IgG1, and RDI-IgG2.
doi:10.1371/journal.pone.0034611.g006
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Blood was collected at various time points post-injection, up to
1 hour for rats dosed with RDI and up to 7 days for rats dosed
with RDI-eIgG1. Blood samples were placed on ice upon
collection and then centrifuged at 4uC at 12,000 RPM for
15 minutes. The plasma was collected and stored at 220uC until
assayed.
ELISA quantitation and analysis. The half-lives of the RDI
and RDI-eIgG1 proteins were determined by capture ELISA
assay. Briefly, Immulon 2-HB microtiter plates (Dynex
Technologies, Inc.) were coated with 1 mg per well of PA83 (List
Labs), and then blocked with 3% non-fat dry milk in TBS
(pH 7.0). Plasma samples taken from study animals and diluted
1:10 in PBS were added to wells and incubated for 1 hour at room
temperature. RDI and RDI-eIgG1 were mixed with 10% rat
serum in PBS and used as standard controls. The standard and test
samples were each assayed in triplicate. The plates containing the
RDI samples were incubated at room temperature for 1 hour with
a chicken anti-ANTXR2 antibody [27] diluted 1:100 in 1% non-
fat dry milk in TBS with 0.05% Tween 20, and then for 1 hour
with biotin-conjugated goat anti-chicken antibody (Vector) diluted
1:20,000 in 1% non-fat dry milk in TBS with 0.05% Tween 20.
The plates containing the RDI-eIgG1 samples were incubated at
room temperature for 1 hour with a biotin-conjugated goat anti-
hIgG (Southern Biotech, Birmingham, AL) diluted 1:20,000 in 1%
non-fat dry milk in TBS with 0.05% Tween 20. All plates were
incubated with streptavidin-alkaline phosphatase (GE Healthcare
Bio-Sciences Corp., Piscataway, NJ) diluted 1:5,000 in TBS for
45 minutes followed by a 20 minute incubation at 37uC with p-
nitriphenyl phosphate substrate (Sigma-Aldrich, St. Louis, MO).
Finally, 2 N NaOH was added and the absorbance values of each
sample measured at 405 nm with a plate reader (Molecular
Devices, Sunnyvale, CA). The average mean values of the
triplicate samples were calculated and values of the standard
sample without RDI or RDI-eIG1 was subtracted from each
measurement. The measurements obtained with the known
standard amounts of RDI and RDI-eIgG1 were graphed and
the trendline equation was used to calculate the concentrations of
the receptor decoy proteins in the different plasma samples as a
function of time. Pharmacokinetic parameters were calculated
using one-phase exponential decay (Graph Pad Prism, GraphPad
Inc. La Jolla CA).
In vivo intoxication assay in rats
Male 200 gram HSD rats (Harlan Laboratories, Indianapolis,
IN) were co-injected i.v. with LeTx (40 mgP A +12 mg LF;
established minimal lethal dose (MLD) [28]) and either PBS,
19 mg RDI, or 49 mg of either RDI-eIgG1, RDI-IgG1, or RDI-
IgG2. These amounts of the receptor decoy proteins are equal to a
2:1 molar ratio (VWA/I domain: PA). Rats were monitored and
time of death recorded. Statistical analysis was performed using
Prism (Graph Pad, Inc., La Jolla, CA)
Toxicity testing RDI-eIgG1 in rats
Male 200 gram HSD rats (Harlan Laboratories, Indianapolis,
IN) were injected i.v. with 123 mg RDI-eIgG1, which corresponds
to a 5:1 molar ratio of ANTXR2 VWI/I domain: PA. Blood
samples were collected before injection and 15 hours and two days
post injection and tested in a standard chemistry panel
(Department of Animal Resources, The Scripps Research
Institute.) Tissue was collected, sectioned, and stained with
hematoxylin and eosin Y.
Circulation and recovery of LeTx and RDI-eIgG1 in vivo
Male 200 gram HSD rats (Harlan Laboratories, Indianapolis,
IN) were anesthetized with isofluoranes, pre-bled, and then
injected through jugular vein cannulas with a total volume of
500 ml containing 40 mg PA, 12 mg LF, and 122 mg of RDI-eIgG1
in PBS. Blood was collected 15 hours after injection and serum
was prepared and immediately used to precipitate RDI-eIgG1
using a protein G immunoprecipitation kit (Roche Diagnostics,
Mannheim, Germany). The positive control used for this assay was
serum from a non-injected control rat, spiked with 3.07 mg RDI-
eIgG (Young Lab), 1.0 mg PA (List Biological Labs, Campbell,
CA), and 0.3 mg LF(List Labs). The protein G agarose beads were
incubated with 500 ml serum samples for 2 hours at room
temperature with constant agitation, briefly spun down, and the
beads were washed with 1 ml wash buffer four times. 50 ml
Laemmli buffer containing ß-mercaptoethanol was added to each
precipitated bead sample and the samples were vortexed, boiled
for 10 minutes, briefly centrifuged, and the supernatants collected
and stored at 220uC.
Virulence testing in the mouse infection model. Female
A/J mice, approximately 8–10 weeks old, were challenged
intraperitoneally (IP) B. anthracis Sterne strain spores, delivered in
sterile water for injection. The mice received approximately
3.9610
4 spores and were then monitored for signs of clinical illness
or death for 14 days after the challenge. These data were used to
calculate the survival curves and mean times to death or
euthanasia. The Sterne strain spores used for the challenge were
prepared using Leighton and Doi medium as previously described
[29].
Immunoblot for PA, RDI-eIgG1, and LF. Samples
(100 ng) were analyzed by immunoblotting using NuPage 4–
12% Bis-Tris 10 well mini gels with MOPS SDS running buffer
(Invitrogen, Inc.). Positive control samples were prepared with
100 ng of either RDI-eIgG1, PA83, or LF contained in 15 ml
loading buffer. A serum-only negative control sample was
prepared by mixing equal parts rat serum from the pre-bleed
samples with loading buffer. All samples were boiled for 5 minutes,
loaded into wells of a 4–12% SDS-containing polyacrylamide gel
and electrophoresed at 200 V for 45 minutes. The protein samples
were transferred to PVDF membranes using a Trans-Blot cell
(Bio-Rad) at 10 V overnight. Membranes were washed in PBS-
Figure 7. Delayed toxicity of rats following LeTx challenge with
RDI-IgG1 and RDI-IgG2 fusion proteins. Male 200 gram HSD rats
(5/group) were co-injected i.v. with LeTx (40 mgP A +12 mg LF) and
either 19 mg of RDI; or 49 mg of either RDI-eIgG1, RDI-IgG1, or RDI-IgG2.
Rats were monitored and time of death recorded.
doi:10.1371/journal.pone.0034611.g007
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1 hour at room temperature. Primary antibodies were prepared in
10 ml 2% milk in PBST per membrane with either a 1:1000
dilution of a chicken anti-ANTXR2 antibody [27] a 1:250 dilution
of a goat anti-PA antibody (List Laboratories, Campbell, CA), or a
1:250 dilution of a goat anti-LF antibody (List Laboratories,
Campbell, CA). Membranes were incubated with the primary
antibody samples at 4uC overnight on a shaking platform, washed
with PBST, and then incubated at room temperature for 1 hour
with either HRP- anti-chicken, or HRP- anti-goat, secondary
antibodies. Membranes were then washed with PBST and
incubated with the SuperSignal West Pico chemiluminescent
substrate (Thermo Scientific, Rockford, IL) for 5 minutes
according to the manufacturer’s instructions. Then membranes
were then exposed to X-ray film for 5 mins at room temperature
and developed.
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